^
Association details:
| Biomarker: | KIT exon 17 mutation |
|---|---|
| Cancer: | Thymic Carcinoma |
| Drug: | Ayvakit (avapritinib) (CSF-1R inhibitor, PDGFR antagonist, mutant c-KIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy
Published date:
07/09/2022
Excerpt:
Two patients harboured mucosal melanoma and the other two were diagnosed with thymic carcinoma....We describe a differential activity of avapritinib (3/4 patients responded, 1/4 did not respond)...Taken together, the inactivity of imatinib on KIT exon 17 mutations, the general low clinical efficacy of immunotherapy, as well as the consequent formal lack of standard available and active second line systemic treatments in both mucosal melanoma and thymic carcinoma, support the implementation of avapritinib in the therapeutic armamentarium.
DOI:
10.1016/j.ejca.2022.06.015
